Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice

Urology

Volumn 56, Issue 3, 2000, Pages 521-526

  Beecken, Wolf Dietrich C ^a,b   Fernandez, Antonio ^a,b   Panigrahy, Dipak ^a,b   Achilles, Eike Gert ^a,b   Kisker, Oliver ^a,b   Flynn, Evelyn ^a,b   Joussen, Antonia M ^a,b   Folkman, Judah ^c   Shing, Yuen ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CATTLE; CELL DIVISION; CYCLOHEXANES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; SESQUITERPENES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0033831043     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00642-7     Document Type: Article

References (24)

1. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer a contemporary review of the literature . J Urol. 160:1998;645-659.
2. Messing E.W., Catalona W. Urothelial tumors in the urinary tract. Walsh P.C., Retik A.B., Vaughan E.D. Jr, et al. 7th ed. Campbell's Urology. vol 3:1998;2327-2410 WB Saunders, Philadelphia.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
4. Folkman J., Shing Y. Angiogenesis. J Biol Chem. 267:1992;10931-10934.
5. Folkman J. Tumor angiogenesis therapeutic implications . N Engl J Med. 285:1971;1182-1186.
6. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma . Cell. 79:1994;315-328.
7. O'Reilly M.S., Holmgren L., Chen C.C. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
8. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin an endogenous inhibitor of angiogenesis and tumor growth . Cell. 88:1997;277-285.
9. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
10. Ingber D., Fujita T., Kishimoto S., et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppresses tumor growth. Nature. 348:1990;555-557.
11. Fujioka T., Hasegawa M., Ogiu K., et al. Antitumor effects of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J Urol. 155:1996;1775-1778.
12. Folkman J: Tumor angiogenesis, in Wells SA Jr, and Sharp PA (Eds): Accomplishments in Cancer Research 1997. Philadelphia, Lippincott, Williams & Wilkins, 1998, pp 32-44.
13. Kimiya K., Naito S., Soejima T., et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol. 148:1992;441-445.
14. Lin C.-W., Lin J.C., Prout G.R. Jr. Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res. 45:1985;5070-5079.
15. Folkman J., Haudenschild C.C., Zetter B. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA. 76:1979;5217-5221.
16. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma . N Engl J Med. 324:1991;1-9.
17. Jones P.A., Droller M.J. Pathways of development and progression in bladder cancer new correlation between clinical observation and molecular mechanisms . Semin Urol. 11:1993;177-192.
18. O'Brien T., Cranston D., Fuggle S., et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55:1995;510-513.
19. Ishida K., Yoshimura N., Mandai M., et al. Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model. Invest Ophthamol Vis Sci. 40:1999;1512-1519.
20. Sin N., Meng L., Wang M.Q.W., et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA. 94:1997;6099-6103.
21. Watson J.C., Sutanoto-Ward E., Osaku M., et al. Importance of timing and length of administration of angiogenesis inhibitor TNP-470 in the treatment of K12/TRb colorectal hepatic metastases in BD-IX rats. Surgery. 126:1999;358-363.
22. Takamiya Y., Friedlander R.M., Brem H., et al. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg. 78:1993;470-476.
23. Tanaka Y., Kawamata H., Fujimoto K., et al. Angiogenesis inhibitor TNP-470 suppresses tumorigenesis in rat urinary bladder. J Urol. 157:1997;683-688.
24. Osawa S., Terashima Y., Kimura G., et al. Antitumor effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N(4-hydroxybutyl) nitrosamine. Br J Urol Int. 83:1999;123-128.